| Code | CSB-RA025857MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Burfiralimab, targeting vimentin (VIM), a type III intermediate filament protein that plays crucial roles in maintaining cell structure, integrity, and mechanical stability. Vimentin is predominantly expressed in mesenchymal cells and serves as a key marker of epithelial-mesenchymal transition (EMT), a process fundamental to embryonic development, wound healing, and cancer metastasis. Aberrant vimentin expression has been implicated in various pathological conditions, including fibrotic diseases, inflammatory disorders, and multiple cancer types where it contributes to tumor invasion, metastasis, and therapeutic resistance.
Burfiralimab is a humanized anti-VIM monoclonal antibody . It is under clinical phase I/II research stage and is developed to explore the potential for treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It binds to vimentin in the tumor microenvironment and blocks its interaction with the inhibitory immune checkpoint VISTA, thereby relieving immune suppression and activating the anti-tumor immune response. This biosimilar provides researchers with a reliable tool for investigating vimentin biology, studying EMT mechanisms, evaluating vimentin as a biomarker in disease progression, and exploring anti-vimentin therapeutic strategies. The antibody enables comprehensive studies of vimentin's role in cellular processes and disease pathogenesis across multiple research contexts.
There are currently no reviews for this product.